As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
7 Analysts have issued a Phio Pharmaceuticals Corp. forecast:
7 Analysts have issued a Phio Pharmaceuticals Corp. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -8.39 -8.39 |
11%
11%
|
|
| EBIT (Operating Income) EBIT | -8.36 -8.36 |
10%
10%
|
|
| Net Profit | -7.95 -7.95 |
7%
7%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
| Head office | United States |
| CEO | Robert Bitterman |
| Employees | 5 |
| Founded | 2011 |
| Website | phiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


